Antagonist G-mediated targeting and cytotoxicity of liposomal doxorubicin in NCI-H82 variant small cell lung cancer

Brazilian Journal of Medical and Biological Research

Volumn 37, Issue 8, 2004, Pages 1185-1192

  Moreira, J N ^a   Gaspar, R ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Antagonist G; Doxorubicin; Lung cancer; Pegylated liposomes; Targeting

Indexed keywords

ANTAGONIST G; DOXORUBICIN; HEXAPEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; COVALENT BOND; DRUG BINDING; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG TARGETING; ENCAPSULATION; ENDOCYTOSIS; FLUOROMETRY; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; INTERNALIZATION; ISOTOPE LABELING; LUNG SMALL CELL CANCER; MITOSIS INHIBITION; TEMPERATURE MEASUREMENT;

EID: 4444282289     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2004000800008     Document Type: Article

References (24)

1. s6k-dependent pathway. Cancer Research, 58: 5239-5247.
2. Worden FP & Kalemkerian GP (2000). Therapeutic advances in small cell lung cancer. Expert Opinion on Investigational Drugs, 9: 565-579.
3. Moody TW & Cuttitta F (1993). Growth factor and peptide receptors in small cell lung cancer. Life Sciences, 52: 1161-1173.
4. Sethi T, Langdon S, Smyth J & Rozengurt E (1992). Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Research, 52s: 2737s-2742s.
5. Seckl MJ, Newman RH, Freemont PS & Rozengurt E (1995). Substance P-related antagonists inhibit vasopressin and bombesin but not 5′-3-O-(thio)triphosphate-stimulated inositol phosphate production in Swiss 3T3 cells. Journal of Cellular Physiology, 163: 87-95.
6. Woll PJ & Rozengurt E (1990). A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro. Cancer Research, 50: 3968-3973.
7. Lopes de Menezes DE, Pilarski LM & Allen TM (1998). In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Research, 58: 3320-3330.
8. Park JW, Hong K, Kirpotin DB et al. (2002). Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clinical Cancer Research, 8: 1172-1181.
9. Moreira JN, Hansen CB, Gaspar R & Allen TM (2001). A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochimica et Biophysica Acta, 1514: 303-317.
10. Gazdar AF, Carney DN, Nau MM & Minna JD (1985). Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Research, 45: 2924-2930.
11. 1a- receptors in variant SCCL. Cancer Letters, 82: 167-174.
12. Daleke DL, Hong K & Papahadjopoulos D (1990). Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochimica et Biophysica Acta, 1024: 352-366.
13. Olson F, Hunt CA, Szoka FC, Vail WJ & Papahadjopoulos D (1979). Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochimica et Biophysica Acta, 557: 9-23.
14. Bolotin EM, Cohen R, Bar LK, Emanuel N, Ninio S, Lasic DD & Barenholz Y (1994). Ammonium sulphate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. Journal of Liposome Research, 4: 455-479.
15. Bartlett GR (1959). Phosphorus assay in column chromatography. Journal of Biological Chemistry, 234: 466-468.
16. Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65: 55-63.
17. Lopes de Menezes DE, Kirchmeier MJ, Gagne JF, Pilarski LM & Allen TM (1999). Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells. Journal of Liposome Research, 9: 199-228.
18. Rygaard K, Vindeløv LL & Spang-Thomsen M (1993). Expression of myc family oncoproteins in small-cell lung-cancer cell lines and xenografts. International Journal of Cancer, 54: 144-152.
19. Brambilla E, Moro D, Gazzeri S, Brichon PY, Nagy-Mignotte H, Morel F, Jacrot M & Brambilla C (1991). Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma. Journal of Clinical Oncology, 9: 50-61.
20. Bunn Jr PA, Chan D, Dienhart DG, Tolley R, Tagawa M & Jewett PB (1992). Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity. Cancer Research, 52: 24-31.
21. DeFrees SA, Phillips L, Guo L & Zalipsky S (1996). Sialyl Lewis x liposomes as a multivalent ligand and inhibitor of E-selectin mediated cellular adhesion. Journal of the American Chemical Society, 118: 6101-6104.
22. Kirchmeier MJ, Ishida T, Chevrette J & Allen TM (2001). Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay. Journal of Liposome Research, 11: 15-29.
23. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A & Barenholz Y (1994). Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Research, 54: 987-992.
24. North WG, Fay MJ, Longo KA & Du J (1998). Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide. Cancer Research, 58: 1866-1871.